Henney highlights priorities for cash-strapped FDA as she embraces the letter and spirit of the law
This article was originally published in Clinica
The FDA's new commissioner, Jane Henney, said in her first major public speech in the US last week that she would focus on five top priorities: blood safety; tobacco regulation; food safety; implementation of the FDA Modernization Act of 1997(FDAMA); and promoting the agency's scientific base. In her brief remarks at the Food and Drug Law Institute's annual meeting she made no mention of the medical device industry.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.